drugset

drugset / Trial / NCT06095115

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115 ↗

Phase 3 Active not recruiting 684 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Timeline

Start: 2023-10-12
Primary completion: 2024-07-29
Completion: 2027-04-06

Outcome

Met primary endpoint

paper At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response PMID 41191940 ↗

paper 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons). PMID 41191940 ↗

Publications

Bissonnette R, Soung J, Hebert AA, Pink AE, Pinter A, Moore AY, Shi Y, Wang WH, Toth DP, Miller-Kassamali M, Cafone J, Jiang J, Li S, DeKlotz CMC, Nunes F, Lebwohl MG. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med. 2025 Nov 6;393(18):1784-1795. doi: 10.1056/NEJMoa2504187.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotrokinra	Peptide	200 mg	Oral

Indications